Why Farbe Firma is the Top Manufacturer of Famotidine Injection
- Maulik Sudani
- 6 hours ago
- 7 min read
Last Updated: June 12, 2026
TL;DR: Famotidine Injection — a sterile, clear aqueous solution of famotidine, a histamine H2-receptor antagonist (H2 blocker), supplied commonly as 20 mg/2 mL single-dose ampoules or vials (10 mg/mL) for slow intravenous injection or as a concentrate for dilution and infusion — is a workhorse hospital agent for acid suppression when the oral route is not available: stress-ulcer prophylaxis in critically ill patients, gastro-oesophageal reflux disease, peptic ulcer disease, acid-hypersecretory conditions, and reduction of gastric acidity before anaesthesia. Famotidine is supplied as a low-volume parenteral solution buffered to a controlled, slightly acidic pH with L-aspartic acid, is sensitive to light and must stay clear and free of particulates, so each ampoule or vial must deliver an exact, sterile, particulate-free dose at the labelled concentration. Its safety and shelf life depend on a precise stability-indicating assay, a tightly controlled impurity and degradation profile, accurate pH and fill-volume control, light protection, low particulate and endotoxin, a validated sterilisation route and verified container-closure integrity. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Famotidine Injection at our Gujarat, India facility and supplies it to hospital pharmacy, critical-care, surgical and gastroenterology services, tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Histamine H2-receptor antagonist (H2 blocker) — Famotidine Injection suppresses gastric acid secretion for stress-ulcer prophylaxis in critically ill patients, GERD, peptic ulcer disease, acid-hypersecretory conditions and reduction of gastric acidity before anaesthesia, delivering reliable acid control by intravenous injection or infusion when oral therapy is not feasible.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, light-protected solution compounding and ampoule/vial filling lines, dedicated control of the stability-indicating assay, the impurity profile, solution pH, fill volume, particulate and endotoxin for a light-sensitive low-volume parenteral solution, with container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, ICH Q1B photostability data, sterilisation and container-closure data, drug master files and CEP-style documentation for registrations including ministry-of-health, hospital-formulary and institutional tenders.
End-to-end CDMO services: Sterile-solution contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tamper-evident tender-ready ampoule and vial packaging and import/export coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Famotidine Injection Demands a Premium Manufacturer
Famotidine Injection occupies a dependable, everyday place in critical care, surgery, emergency medicine and gastroenterology across every market. It is the intravenous histamine H2-receptor antagonist that clinicians reach for when acid suppression is needed and the patient cannot take medicine by mouth — for stress-ulcer prophylaxis in the intensive-care unit, in gastro-oesophageal reflux disease and peptic ulcer disease, in acid-hypersecretory states, and to reduce gastric acidity before anaesthesia. Given as a slow intravenous injection from a small-volume ampoule or vial, or diluted into an infusion, famotidine blocks the histamine H2 receptors on the gastric parietal cells and reduces acid output dependably. In each of these settings the dose delivered from each ampoule or vial must be exact, sterile, particulate-free and reliably the same from unit to unit, because in a critically ill patient acid control is part of preventing a dangerous gastrointestinal bleed.
That clinical reality places real demands on the manufacturer. Famotidine is presented as a low-volume aqueous solution — typically 20 mg in 2 mL — buffered to a controlled, slightly acidic pH with L-aspartic acid so the molecule stays stable and soluble, and it must remain a clear, essentially colourless solution throughout shelf life. The assay must be exact; the impurity and degradation profile must stay within tight limits; the pH and the deliverable volume must be controlled tightly so each ampoule gives the labelled dose; the solution must be free of visible and sub-visible particulates and low in endotoxin; the product must be protected from light; and it must be sealed in an ampoule or vial whose container-closure integrity holds across shelf life. Choosing a Famotidine Injection manufacturer that treats the stability-indicating assay, pH and fill-volume control, light protection, the validated sterilisation route, particulate and endotoxin control and container-closure integrity as core engineering disciplines is what protects the patient at the point of care.
What Sets a World-Class Famotidine Injection Manufacturer Apart
A world-class manufacturer of Famotidine Injection invests in three areas that weaker suppliers underfund: a precise, stability-indicating assay of famotidine with the tight related-substance and degradation-product control by HPLC that a low-volume parenteral demands, a robust, validated aseptic solution-fill process — with terminal moist-heat sterilisation where the formulation and container permit it, otherwise sterile filtration and aseptic filling — that protects the assay, the pH and the clarity of the solution, and tender-ready dossier support for a hospital-formulary product procured through pharmacy and ministry-of-health channels. It starts with the active — pharmacopoeial-grade famotidine sourced from qualified, audited API makers, with full assay, related-substance and impurity profiling and certificates of analysis verified by the receiving laboratory before the material enters production.
Compounding and filling then have to defend both the assay and the dose. The bulk solution is compounded in water-for-injection with the L-aspartic acid buffer system at the controlled, slightly acidic pH that keeps famotidine stable and soluble, sterile-filtered through 0.22 µm membrane, and filled into ampoules or vials under light-protected ISO Class 5 conditions, with the validated sterilisation route — terminal moist-heat where qualified, otherwise full aseptic processing — locked in the master batch record. Filled units are 100 % inspected for fill, seal, clarity and particulate defects; in-process and release testing confirm famotidine assay by validated HPLC, the related-substance profile, solution pH, deliverable volume, visible and sub-visible particulate matter, and endotoxin is held well within limits so the injection is safe for intravenous administration. Because famotidine is light-sensitive, the compounding, holding and filling steps and the finished pack are all protected from light.
Quality Systems Behind Every Famotidine Injection
Every Farbe Firma Famotidine Injection batch is released only after a full stack of quality checks: stability-indicating HPLC assay of famotidine against pharmacopoeial reference standards, control of related substances and degradation products by HPLC, solution pH, deliverable (fill) volume, clarity and colour of the solution, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, and container-closure integrity for the ampoule or vial format. Certificates of analysis are issued with full traceability back to the API lot, the primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, validated sterilisation and depyrogenation equipment, light-protected (low-actinic) compounding and filling areas, validated ampoule- and vial-filling lines with 100 % inspection, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because famotidine is light-sensitive and its assay, pH, clarity and particulate burden drive both efficacy and safety, we treat the stability-indicating HPLC assay, the solution pH, the deliverable volume and the related-substance profile as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under both long-term (25 °C / 60 % RH) and accelerated (40 °C / 75 % RH) ICH Q1A conditions, with ICH Q1B photostability challenge, and the product is protected from light through its ampoule or vial labelling and secondary packaging.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Famotidine Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables, including a broad small-volume parenteral portfolio across gastrointestinal, critical-care, anti-infective and supportive-care categories. For Famotidine Injection specifically, we supply 20 mg/2 mL single-dose ampoules and vials of sterile solution under WHO-GMP conditions, with country-specific strengths, fill configurations, ampoule or vial formats, tamper-evident packs and pack counts available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier — including the stability-indicating-assay, pH, sterilisation and container-closure data package — ready to hand for registration and tender qualification.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, assay and related-substances method-validation data, sterilisation and container-closure reports, translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics to the destination market. When a buyer needs Famotidine Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, validation reports, light-protected artwork, line slot and shipment plan delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and into the compounding and filling suites; our quality unit answers technical queries with primary data, not slogans; and our reviewer team — practising pharmacists and R&D scientists — can talk through API sourcing, stability-indicating assay development, related-substance and degradation control, buffer and pH design, the choice between terminal sterilisation and aseptic filling, fill-volume and deliverable-dose control, light-protection strategy, particulate and endotoxin control, container-closure integrity and shelf-life choices in real detail. For a light-sensitive low-volume parenteral where assay accuracy, pH and particulate control directly govern both effect and safety, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Famotidine Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Famotidine Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, light-protected solution compounding and ampoule/vial filling lines, validated sterilisation, qualified water-for-injection systems, 100 % inspection and continuous environmental monitoring.
Which strengths and pack sizes of Famotidine Injection do you supply?
Our standard presentation is the 20 mg/2 mL (10 mg/mL) single-dose ampoule or vial of sterile famotidine solution for slow intravenous injection or dilution before infusion. Custom strengths, fill configurations, ampoule or vial formats, tamper-evident counts per pack and country-specific artwork are available under contract manufacturing agreements.
Is Famotidine Injection a ready-to-use solution or a powder for reconstitution?
Famotidine Injection is a clear aqueous solution, not a lyophilized powder. It is supplied in low-volume ampoules or vials for slow intravenous injection, or as a concentrate to be diluted into an infusion. Farbe Firma controls the solution pH with an L-aspartic acid buffer, protects it from light, and verifies assay, clarity, deliverable volume and particulate matter at release.
Can Farbe Firma support country-specific registrations for Famotidine Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, assay and related-substances method-validation data, sterilisation and container-closure reports, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations and tender qualification in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
What is the minimum order quantity for Famotidine Injection contract manufacturing?
MOQs vary by strength, ampoule or vial size, sterilisation route, label complexity and dossier requirements. For our small-volume parenteral presentations we accommodate hospital-scale and full national-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments